Product categories
Nuclear Medicine
123I MIBG BACON (R&D)
Name:
123I MIBG Bacon (R&D)
Active Principle:
123I- Meta Iodo Benzylguanidine or 123I- Iobenguane
Therapeutic Action:
It is indicated for: Oncology:
a) Scintigraphic localization of tumors originating in tissues that derive embryologically from the neural crest. These are pheochromocytomas, paragangliomas, chemodectomas, and angioneuromas.
b) Detection, staging and monitoring of response to treatment of neuroblastomas.
c) Evaluation of iobenguane uptake in pheochromocytomas, euroblastomas, carcinoid tumors and medullary thyroid carcinoma. The sensitivity for diagnostic visualization differs according to the pathology.
d) Functional studies of hyperplasia of the adrenal medulla
Cardiology: Functional studies of the sympathetic innervation of the myocardium. This drug can be used as a prognostic indicator of the risk of progression of heart failure, the appearance of life-threatening arrhythmic events, or sudden cardiac death in patients with heart failure in functional class II/III of the NYHA (New York Heart Association). ) and left ventricular dysfunction.
Nuclear Medicine
123I MIBG BACON (R&D)
Name:
123I MIBG Bacon (R&D)
Active Principle:
123I- Meta Iodo Benzylguanidine or 123I- Iobenguane
Therapeutic Action:
It is indicated for: Oncology:
a) Scintigraphic localization of tumors originating in tissues that derive embryologically from the neural crest. These are pheochromocytomas, paragangliomas, chemodectomas, and angioneuromas.
b) Detection, staging and monitoring of response to treatment of neuroblastomas.
c) Evaluation of iobenguane uptake in pheochromocytomas, euroblastomas, carcinoid tumors and medullary thyroid carcinoma. The sensitivity for diagnostic visualization differs according to the pathology.
d) Functional studies of hyperplasia of the adrenal medulla
Cardiology: Functional studies of the sympathetic innervation of the myocardium. This drug can be used as a prognostic indicator of the risk of progression of heart failure, the appearance of life-threatening arrhythmic events, or sudden cardiac death in patients with heart failure in functional class II/III of the NYHA (New York Heart Association). ) and left ventricular dysfunction.
